secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2023-06-21T23:59:59+00:00
Accession:  0001171843-23-004019
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Corvus Pharmaceuticals holds 2023 annual meeting; elects directors and ratifies auditor
--------------------------------------------------------------------------------

- Stockholders elected Richard A. Miller, M.D. and Linda S. Grais, M.D., J.D. as Class I directors for three-year terms.
- Ratified PricewaterhouseCoopers as independent auditor for FY2023 with 35.9M votes for, 0.1M against.
- Non-binding advisory vote on executive compensation passed with 25.6M for, 0.4M against.
- Total shares voted: 36.2M of 46.6M outstanding (77.6% turnout).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184323004019/0001171843-23-004019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184323004019/f8k_062023.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-004019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer